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spinal fluid from patients with Alzheimer’s disease
and mild cognitive impairment
Keld Poulsen1, Justyna MC Bahl1, Anja H Simonsen2, Steen G Hasselbalch2 and Niels HH Heegaard1,3*Abstract
Background: Transthyretin (TTR), an abundant protein in cerebrospinal fluid (CSF), contains a free, oxidation-prone
cysteine residue that gives rise to TTR isoforms. These isoforms may reflect conditions in vivo. Since increased oxidative
stress has been linked to neurodegenerative disorders such as Alzheimer’s disease (AD) it is of interest to characterize
CSF-TTR isoform distribution in AD patients and controls. Here, TTR isoforms are profiled directly from CSF by an
optimized immunoaffinity-mass spectrometry method in 76 samples from patients with AD (n = 37), mild cognitive
impairment (MCI, n = 17)), and normal pressure hydrocephalus (NPH, n = 15), as well as healthy controls (HC, n = 7).
Fractions of three specific oxidative modifications (S-cysteinylation, S-cysteinylglycinylation, and S-glutathionylation)
were quantitated relative to the total TTR protein. Results were correlated with diagnostic information and with levels
of CSF AD biomarkers tau, phosphorylated tau, and amyloid β1−42 peptide.
Results: Preliminary data highlighted the high risk of artifactual TTR modification due to ex vivo oxidation and thus the
samples for this study were all collected using strict and uniform guidelines. The results show that TTR is significantly
more modified on Cys(10) in the AD and MCI groups than in controls (NPH and HC) (p ≤ 0.0012). Furthermore, the
NPH group, while having normal TTR isoform distribution, had significantly decreased amyloid β peptide but normal
tau values. No obvious correlations between levels of routine CSF biomarkers for AD and the degree of TTR
modification were found.
Conclusions: AD and MCI patients display a significantly higher fraction of oxidatively modified TTR in CSF than the
control groups of NPH patients and HC. Quantitation of CSF-TTR isoforms thus may provide diagnostic information in
patients with dementia symptoms but this should be explored in larger studies including prospective studies of MCI
patients. The development of methods for simple, robust, and reproducible inhibition of in vitro oxidation during CSF
sampling and sample handling is highly warranted. In addition to the diagnostic information the possibility of
using TTR as a CSF oxymeter is of potential value in studies monitoring disease activity and developing new drugs
for neurodegenerative diseases.
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Table 1 Summary of demographic data for samples
included in this study
AD MCI NPH HC
n (male/female) 37 (22/15) 17 (12/5) 15 (12/3) 7 (4/3)
Age (years)a 71 ± 9 71 ± 9 76 ± 7* 62 ± 12*
Age range (min-max) 45-88 55-89 63-85 51-88
aMean ± SD. The asterisk indicate a significant difference with p < 0.05 between
the NPH and HC groups (Mann–Whitney U test).
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Alzheimer’s disease (AD) is the most common type of
dementia. The estimated worldwide prevalence of AD was
36.6 million in 2010 and is estimated to increase to 115
million in 2050 [1]. AD is heterogeneous both at clinical
and neuropathological levels [2]. Considerable research
efforts are aimed at developing better therapies tailored
for the individual patients [3]. For this and for the sake
of the patient’s quality of life accurate diagnostic tools
are needed, especially in early phases characterized by
mild cognitive impairment (MCI) and episodic memory
loss that may also be a manifestation of a plethora of
other conditions. Today, the AD diagnosis relies on a
combination of clinical, imaging, and laboratory criteria
[4,5] the latter being cerebrospinal fluid (CSF) levels of
amyloid beta 1−42 peptide (Aβ1−42), tau protein (t-tau),
and tau specifically phosphorylated at Thr-181 (p-tau181).
The laboratory tests, however, perform less than satisfac-
tory in the early diagnosis of sporadic AD. Thus, many
studies focus on developing new biomarkers for AD but
no consistently reproducible results about CSF peptide,
protein, lipid and metabolite biomarker candidates are
available. One potential marker is the most abundant CSF
protein transthyretin (TTR). This protein is prone to
modifications on its free Cys (10) residue and thus may
reflect oxidative stress. Oxidative stress and the presence
of reactive oxygen species (ROS) are involved in AD
pathogenesis. However, results in the literature are con-
flicting on TTR concentrations and quantitative propor-
tions of the cysteine oxidations [6-12]. Thus, some studies
indicate that TTR concentrations in CSF are altered in
AD [13,14] and decrease during AD progression [15-17].
In contrast, CSF-TTR is reported to increase during
normal aging [18]. Accordingly, we worked out a method
for high-resolution mass spectrometry (MS) of intact TTR
where a polyclonal antibody is used to capture all TTR
isoforms. Using on-line immunoaffinity (IA) chroma-
tography of crude serum analysed with electrospray
ionization (ESI) time-of-flight (TOF) mass spectrometry
(MS) the method was initially used to characterize TTR-
amyloidosis [19]. The method was modified using immu-
noprecipitation (IP) of TTR directly from crude CSF to
minimize ex vivo protein artifacts [20]. The aim of the
present study was to investigate the thiol-conjugated TTR
isoforms as support for the differential diagnosis of AD and
related dementias by applying the method on clinically
well-characterized samples collected under uniform and
highly controlled conditions. The samples represent AD
patients and selected controls (MCI, normal pressure
hydrocephalus (NPH) and healthy controls (HC)). The
MCI group was a heterogeneous mix of cognitive impaired
patients, some later developing AD and others stabilizing
at a mild level of cognitive impairment, not reaching AD
[21,22]. NPH constitutes an important control group thatalso may present with symptoms of cognitive impairment.
NPH usually develops in individuals past 60 years of age
and is due to an abnormal accumulation of CSF in the
brain ventricles. Although the cognitive deficiency in NPH
is not necessarily associated with disturbances in CSF
dynamics, the dementia is potentially reversible by shunt
surgery [23]. Unfortunately, NPH is often misdiagnosed as
AD, Parkinson’s disease or chronic dementia [24] and bet-
ter diagnostic tools for this condition are therefore highly
needed. The final group of controls in this study constitutes
HC that were patients undergoing spinal anaesthesia and
had no signs of dementia or cognitive impairment.
Materials and methods
Participants
A total of 69 patients with symptoms of dementia and 7
non-demented controls were included in the study (Table 1).
The 76 individuals represent four groups: AD, MCI, NPH,
and HC. CSF samples and corresponding clinical and
paraclinical information were obtained from the Danish
Dementia Biobank at the Memory Clinic and Memory
Disorders Research Unit (Copenhagen University Hospital,
Rigshospitalet, DK). According to the guidelines given
by the Ethic committee of the Capital Region of Denmark
patients or their closest relatives gave consent for using
samples for research purposes.
Global cognitive function was assessed using Mini
Mental State Examination (MMSE) [25] and Addenbrooke’s
Cognitive Examination (ACE) [26] scores. Diagnoses were
based on, as a minimum, neurological examination, cranial
CT or MRI, blood and CSF screening tests and cognitive
testing. CSF laboratory analyses included quantitative
immunoassays for Aβ1-42, t-tau and p-tau181. The 37 AD
patients met the NINCDS-ADRDA criteria for probable
AD [27]. The clinical criteria applied for the 17 MCI pa-
tients were those defined by Petersen et al. [28]. The 15
NPH patients presented with the triad of gait disturbance,
urinary incontinence, and dementia/mental decline. NPH
was confirmed by imaging of dilated ventricles in all cases.
These criteria correspond to probable NPH [29]. The 7
healthy controls (HC) were patients that underwent minor
surgery (e.g. hernia repair) under spinal anaesthesia but
that were otherwise physically and mentally healthy with
no evidence of cognitive decline.
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CSF was obtained by lumbar puncture between the 3rd and
4th lumbar vertebrae; withdrawing a total of 10–12 mL.
Samples were obtained between 10 a.m. and 1 p.m. The
first 2 mL were used for routine laboratory analyses. The
remaining CSF was collected into a polypropylene tube and
was mixed gently to avoid gradient effects and immediately
centrifuged at 2000 x g for 10 min to precipitate cells and
other insoluble material. The supernatant was divided in
aliquots of 250 μL in polypropylene cryo-tubes and stored
at −80° within 2 hours after sampling. Samples were
subsequently sub-aliquotted by quick thawing and gentle
mixing of the 250 μL sample, before subdividing into
aliquots of 40–50 μl and placing at −80°C. The samples
were then kept at −80°C until immunoprecipitation of
transthyretin (TTR-IP) was performed.
Quantitative immunoassays of total transthyretin, Aβ1-42,
t-tau and p-tau
Aβ1-42, t-tau and p-tau181 in CSF were quantified using
sandwich ELISA kits (Innotest β-Amyloid(1–42), Innotest
hTAU-Ag and Innotest Phospho-TAU(181p); Innogenetics,
Ghent, Belgium) conducted as described in the vendor
protocols and based on previous studies [30,31]. The
guidelines used for cut-off values were: Aβ1-42 < 550 pg/mL;
t-tau > 300 pg/mL (age < 51 years), t-tau 450 pg/mL
(age 51–70) and t-tau > 530 pg/mL (age > 70); p-tau181
80 pg/mL. The presence of two abnormal out of the
three biomarkers supports the AD diagnosis.
Quantitative rocket immunoelectrophoresis was used
to measure total CSF-transthyretin and was carried out
as follows: One hundred mL of 1.0% (w/v) agarose (HAS,
Litex) in Tris/Tricine electrophoresis buffer was prepared
and allowed to cool to 56°C. A volume of 100 μL poly-
clonal anti human-TTR (Dako A0002, conc. 3.9 mg/ml)
was added to 30 mL of agarose solution and poured onto
10×20 cm glass plate (0.5 μL /cm2). Wells (3 mm diam-
eter) were punched using a gel puncher with suction,
towards one edge of the plate. The wells were placed
towards the cathode. TTR purified from human plasma
was purchased from Sigma-Aldrich (Prealbumin, P1742).
The TTR standard was used to generate a standard
curve consisting of five calibrators (50, 25, 12.5, 6.25
and 3.1 μg/ml). All the CSF samples were diluted 1:1 in
water and 10 μL of diluted standard and CSF samples
were added into the appropriate wells and a constant
voltage of 2.5 V/cm was applied overnight. Then, the
gel was dried and stained with Coomassie blue. The
height of the rocket precipitate was measured from the
upper edge of the well to the tip of the rocket, and a
standard graph was constructed by plotting the concentra-
tion of antigen on Y-axis against the height of the rocket
on X-axis. The concentration of transthyretin in the CSF
samples was calculated by interpolation from this standardcurve. The TTR concentration and TTR isoform charac-
terization (by IA-LC-MS) were in all cases determined
after only one thaw-freeze cycle, i.e., after analyzing for
the AD biomarker panel.
Quantitative analysis of TTR isoforms by nanoLC-ESI-MS
Immunoprecipitation of TTR using a polyclonal rabbit
anti-human antibody and washing steps was performed as
previously described [20] using 40 μL CSF. The lyophi-
lized IP-TTR was solubilized in 20 μl of 30% acetonitrile
(ACN), 0.1% formic acid (FA) (v/v) in water, by two mi-
nutes sonication in a water bath followed by vigorous
vortex mixing. The immunoprecpitate solution was then
separated by a biocompatible Ultimate 3000 nanoLC sys-
tem (Dionex, Thermo Scientific) equipped with an Acclaim
PepMap300 C18 trap column (300 μm id x 5 mm cartridge,
Dionex) and an Acclaim PepMap300 C18 analytical col-
umn (75 μm id × 150 mm long, Dionex) with column
oven temperature set to 45°C. The columns were in a
column-switching set-up with a ten-port switching
valve. Sample (5 μl) was loaded from the autosampler
via a 20 μl sample loop onto the trap column with flow
rate 30 μl/min (2% ACN and 0.1% FA in water) followed
by online pre-concentration and desalting for five mi-
nutes. After column-switching the flow rate was
400 nL/min and sample was eluted to the analytical
column by (A) 2% ACN and 0.1% FA in water, (B) 95%
ACN and 0.1% FA in water: 30% B from 0 to 5 min,
30-100% B from 5 to 59 min (convex gradient 8, Chrome-
leon software, Dionex). An LTQ Orbitrap XL mass spec-
trometer (Thermo Scientific) was used to record the
protein spectra over the mass range of m/z 800–2000
with 3 microscans per scan with a resolution of 60.000
(full-width at half-maximum peak height) at m/z 400.
The sample was introduced through a metal emitter
(ES502) mounted on an ES ion source (ES070) (both
from Proxeon, Thermo Scientifc, DK). The instrument
was operated in positive ESI mode with a spray voltage
of 2.0 kV, tube lens voltage of 250 V and capillary
temperature of 220°C. The MS parameters were optimized
in the range of m/z 800–2000 by infusing TTR purified
from human blood (P1742, Sigma-Aldrich). External
calibration was performed with the ProteoMass CalMix
solution (MSCAL5-1EA, Supelco, Sigma-Aldrich). Raw
spectra covering elution of the four main TTR isoforms
were summarized and subsequently deconvoluted (i.e.
decharged and deisotoped) by the Xtract algorithm within
Qual Browser (Xcalibur ver. 2.0.7, Thermo Scientific) using
the three most intense charge envelopes as described earlier
[20]. The monoisotopic peak heights computed by the
Xtract algorithm were used for calculating the relative
quantities of the TTR isoforms. To calculate the relative
quantities the four monoisotopic peaks were manually
selected (in the case of TTR heterozygotes the 4 double
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the individual sample spectra, with subsequent calculation
of relative amounts as explained previously [20]. Confirm-
ation of the three oxidative thiol modifications on the TTR-
Cys10 was done by reduction with DDT as demonstrated
earlier. Reduction diminished the three peaks to base-
line with simultaneous increase of the TTR-Cys10 non-
modified peak [19]. Validating the chromatographic elution
of the TTR isoforms and identifying the PTMs was per-
formed by tandem MS with subsequent analysis using the
Prosight PTM v2.0 on-line software [32].
Statistical analyses
Differences between the four diagnostic groups were
evaluated (correcting for multiple comparisons) using
the Kruskal-Wallis nonparametric test followed by the
post hoc Dunn’s test. The Mann–Whitney U rank sum test
evaluated the sum of ranks by pairwise comparisons
of diagnostic groups. Correlations were tested by the
Spearman’s rank correlation coefficient. Statistical signifi-
cance was defined as p < 0.05. All statistical analyses were
performed in the Prism ver. 5.03 program (GraphPad Soft-
ware Inc, La Jolla, CA, USA). Multivariate analysis used
the Principal Component Analysis (PCA) algorithm im-
plemented in the Latentix v. 2.11 program (www.latentix.
com). After autoscaling and analysis the PCA scores and
loadings plot data were imported into the GraphPad Prism
program for graphic presentation.
Results
Subjects and samples
Demographic data are summarized in Table 1. The mean
ages between the three dementia disease control groupsA 1-42 (pg/mL)
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I
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Figure 1 CSF biomarkers of AD. CSF Aβ1-42 (A), t-tau (B) and p-tau181 (C
(MCI), normal pressure hydrocephalus (NPH) or healthy controls (HC). Horiz
recommended cut-off levels for the diagnosis of AD; Aβ1-42 < 550 pg/mL, t-tau
significant differences (pairwise analysis by the Mann–Whitney U test) are indic
Exact p values are given below each bracket.were not significantly different while the HC group was
significantly younger than the NPH group (p = 0.011).
All CSF samples had an erythrocyte count < 500/μl. The
CSF total protein concentration exceeded 0.60 g/L in
seven of the 76 patients, four were AD, two were MCI
(both with AD as follow-up diagnosis) and one was NPH
(follow-up diagnosis: NPH combined with apoplexia).
CSF biomarkers for AD
The biomarker panel, Aβ1-42, t-tau, and p-tau181, was mea-
sured in all 76 individual CSF samples (Figure 1). Aβ1-42,
was decreased in all three disease groups as compared
to healthy controls with the lowest value in NPH (p =
0.0002), followed by AD (p = 0.0008) and MCI as least
significant (p = 0.0063). The order of Aβ1-42 concentra-
tions thus was: HC >MCI > AD > NPH (Figure 1A). The
lowest level observed was in the NPH group at 201
(125–304) pg/mL compared to AD 281 (183–418) pg/mL,
MCI 397 (299–678) pg/mL and the HC group 747 (593–
834) pg/mL (median values, 25th–75th percentile).
Compared to the healthy controls (median at 157
(130–187) pg/mL) the level of t-tau was significantly
elevated as expected in the AD group at 423 (226–708)
pg/mL, p = 0.002) and less but still significantly elevated in
the MCI group at 282 (185–542) pg/mL (p = 0.011). The
NPH group at 137 (75–207) pg/mL was not significantly
different from the HC group. The order of t-tau concen-
trations thus were: AD >MCI >HC >NPH (Figure 1B).
The p-tau181 concentrations follow the same rank as
the t-tau concentrations (Figure 1C). The median value
for p-tau181 in HC was 27 (25–28) pg/mL compared to
AD at 69 (43–94) pg/mL (p < 0.0001) and MCI at 56
(37–73) pg/mL (p = 0.0028). Again, the NPH group atg/mL)
NP
H HC
**
*
***
=0.002
p=0.011
0.0006
P-tau181 (pg/mL)
AD MC
I
NP
H HC
0
50
100
150
200
C
***
***
***
**
p<0.0001
p<0.0001
p<0.0001
p=0.0028
) in patients with Alzheimer’s disease (AD), mild cognitive impairment
ontal red bars indicate median values. Horizontal dotted lines indicate
> 450 pg/mL (age 51–70 years) and p-tau > 60 pg/mL [31]. Statistical
ated with horizontal brackets (***, p < 0.001; **, p < 0.01 level; *, p < 0.05).
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Figure 2 Storage time influences TTR oxidation profiles. Deconvoluted spectra of IP-TTR, 0 hours at 4°C before IP (A), IP-TTR, 3 hours at 4°C
before IP (B) and IP-TTR, 6 hours at 4°C before IP (C).
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HC group.
Sample handling for immunoprecipitation (IP)-mass
spectrometric TTR isoform profiling
Preliminary experiments [20] showed the possibility of
using IP-MS to quantitate TTR oxidation isoforms directly
from crude CSF. Before using the approach for analysing
the cohort of samples included in the present study, con-
ditions were worked out to minimize artifactual oxidation.A1
A2
A3
Figure 3 TTR isoform data extraction. Chromatographic elution profiles
TTR isoforms elute with substantial overlap (A1 and B1), from 28 to 34 min
presented for all four TTR isoforms and differential peak elution times can b
calculated and the m/z windows were manually adjusted according to the
routinely 0–3 ppm. Spectra across the four elution peaks were combined (
subsequent semi-quantitative calculations as described in Materials and MeVery pronounced in vitro effects were seen if samples
were kept at room temperature or even at 4°C for few
hours. Thus, Figure 2 shows deconvoluted and superim-
posed spectra from three aliquots of the same sample
sample kept at 4°C for 0, 3 or 6 hours (300 rpm on
horizontal shaker). The peak-heights of TTR-Cys10-Cys
(cysteinylated), TTR-Cys10-CysGly (cysteine-glycinylated),
and TTR-Cys10-SG (glutathionylated) increase propor-
tionally with storage time. These results clearly document
the need for controlled sample handling. Therefore, toB1
B2
B3
from the 3 hour (A) and the 6 hour (B) samples (from Figure 2). The
. In the panels below (A2 and B2) extracted chromatograms are
e observed. For peak extractions the theoretical isoform masses were
precision of the external calibration. The calibration was minor,
A3 and B3). These raw spectra were used for deconvolution and
thods.
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were all collected uniformly and with as short a handling
time and as few thaw-freeze cycles as practically possible
(cf. Materials and methods).
Optimization and data handling on NanoLC ESI Orbitrap
MS of intact TTR isoforms
Data extracted from the chromatographic elution profiles
of the 3 hour (A) and the 6 hour (B) samples (from
Figure 2) are presented in Figure 3. It is observed
(Figure 2A1 and B1) that the TTR isoforms elute with
substantial overlap, almost as one peak. In the extracted
chromatograms (A2 and B2) of all four TTR isoforms dif-
ferential peak elution can be observed. For peak extrac-
tions the theoretical masses of the four isoforms were
calculated using manual adjustment of the m/z windows
according to the precision of the external calibration.
The calibration was routinely on the scale of 0–3 ppm
and only minor adjustments were used. The extraction0 20 40 60 80 100
0
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Figure 4 Altered CSF-TTR isoform profile in AD. Data show CSF total tr
patients with Alzheimer’s disease (AD), mild cognitive impairment (MCI), no
red bars indicate median values. (C) Receiver operating characteristics (ROC
controls (n = 22). Area under curve (AUC) was 0.88 with p-value <0.0001, op
TTR in CSF from patients with AD and the combined control group of NPH
Mann–Whitney U test) are indicated with horizontal brackets (***, p < 0.001windows were: TTR-Cys10 non modified, m/z = 983.926-
983.936; TTR-Cys10-Cys, m/z = 992.426-992.436; TTR-
Cys10-CysGly, m/z = 996.497-996.507 and TTR-Cys10-SG,
m/z = 1005.718-1005.728. In A3 and B3 the summarized
raw spectra across the four elution peaks are shown. These
spectra were used for deconvolution and subsequent
semi-quantitative calculations as described in Materials
and methods. In the previously published method direct
infusion of immunoprecipitated sample to the MS was
used [20] but we find that the infusion flow by itself has
a major impact on the relative abundance of the spectral
peaks (data not shown) (metal emitters have been reported
to cause unwanted sample oxidation [33-35]) and we here
instead use reversed phase separation in line with the
mass spectrometer.
TTR Cys-10 oxidative isoforms
After analyzing all samples by IA-LC-MS as described
data were expressed as the fraction of unmodified TTRAD NPH+HC
0
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%
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*
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ansthyretin (TTR) (A) and the fraction of non-modified TTR (B) in
rmal pressure hydrocephalus (NPH) or healthy controls (HC). Horizontal
) curve. Alzheimer’s disease (AD) (n = 39) were compared HC and NPH
timal cut-off is 72.1% non-modified TTR. (D) Levels of % non-modified
and HC. Statistical significant differences (pairwise analysis by the
; **, p < 0.01 level; *, p < 0.05).
Poulsen et al. Clinical Proteomics 2014, 11:12 Page 7 of 9
http://www.clinicalproteomicsjournal.com/content/11/1/12relatively to the sum of all TTR peak heights in each
sample (Figure 4). When analyzing the same sample
repeatedly the intra-assay variability of this parameter
was up to about 7% (data not shown). Total TTR concen-
tration was between 6.2 and 19.0 μg/mL (overall mean ± 1
SD = 10.1 ± 1.9 μg/mL) with no significant differences
in TTR concentrations between any of the four groups
(Figure 4A). CSF total protein and total TTR were also
tested independently for correlations with patient age
using Spearman’s rank correlation coefficient test in all
four diagnostic groups and none were found (data not
shown). The relative abundance of modified TTR in the
AD and MCI group was tested for correlation with gender
and none was found.
The TTR isoform results (Figure 4B) showed a clear
segregation of the AD and MCI groups from the HC
group and to a lesser extent from the NPH group. Also
the NPH and HC groups differed slightly (p = 0.041).
Thus, TTR was significantly more oxidatively modified
in AD patients compared to the HC group (p = 0.0001)
and compared to the NPH group (p = 0.0002). Likewise,
the relative amount of the fraction of modified TTR in
MCI patients differed significantly from the HC group
(p = 0.0003) and to lesser extend from the NPH group
(p = 0.0012).
The use of the routine CSF-biomarker AD panel alone
with the usual criteria (2 abnormal out of 3 support the
AD diagnosis) gave a diagnostic sensitivity of 57% for
AD and a specificity of AD versus the grouping of NPH
and HC together, of 95%. The TTR oxidation data were
also evaluated for diagnostic performance (AD vs. NPH+
HC) (Figure 4C and D). A cut-off of 72.1% non-modifiedA 
Double
positive
16
Negative
5
AD-panel
positive
5
nm-TTR
<72%
11
Figure 5 Multivariate data analysis. A, Venn diagram illustrating the com
patients diagnosed with probable AD, 32 have abnormal AD panel outcom
this gives a sensitivity of 86% and a specificity of 82% of the AD diagnosis
principal components analysis (PCA) using Aβ1-42 (Aβ), t-tau (tTau), and p-t
data in the Latentix v 2.11 program. Loading vectors are illustrated by arrow
graphic presentation.TTR was found to be optimal in this cohort yielding a
sensitivity and specificity of 73% and 86%, respectively
with a value of 0.88 for the area under the ROC curve
(p < 0.0001) (Figure 4C).
Multivariate analysis
When combining the AD biomarker panel with the TTR
isoform analysis requiring 2 out of 3 parameters of the
AD-panel to be abnormal or the amount of non-modified
TTR to be below <72 for the AD diagnosis, the diagnostic
sensitivity for AD versus the NPH and HC groups was im-
proved to 86% at a specificity of 82%. The Venn diagram
(Figure 5A) illustrates how the 37 AD patients score when
combining the two tests. The relative contribution of the 4
parameters (amyloid β1–42, tTau, pTau, and % non-modified
TTR (nm-TTR)) was assessed by principal components
analysis (PCA) (Figure 5B. The analysis maximizes the
data variability and projects this information into a
two-dimensional subspace between samples (the prinicpal
components (PC) PC1-PC2 score plot) and provide load-
ing vectors that show how variables and the subspace
dimensions relate (Figure 5B). The PCA clearly showed
the ability of the data to completely separate HC (green
dots, Figure 5B) from the AD/MCI group, the inability to
differentiate between AD and MCI, and the pronounced
and differential clustering of NPH samples (orange dots,
Figure 5B) in a group apart from both the HC and
the AD/MCI groups. The loading vectors illustrate
the comparable contribution to sample differentiation
of t-tau and p-tau and the independent contribution of
Aβ1-42 (situated to the upper right quadrant because high
values are associated with non-AD controls). Also, the-2 -1 0 1 2
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http://www.clinicalproteomicsjournal.com/content/11/1/12plot illustrates the direction of the contribution of the
non-oxidized TTR fraction parameter (nm-TTR) that
negatively correlates with pTau and tTau. Finally, Figure 5B
shows that a selective decrease of Aβ1-42 in the presence
of normal values of tau species and almost normal values
of oxidized-TTR fraction is highly specific for NPH cases
in this sample cohort.Discussion and conclusions
The main novel finding in the present study is that the
abundance of oxidized TTR isoforms is significantly in-
creased in CSF from AD and MCI patients as compared
to the HC and the NPH groups. Samples from all patient
and control groups were collected under stringent and
uniform conditions designed to minimize artifactual oxida-
tion. We cannot confirm a finding [36] of decreased levels
of total TTR in CSF from AD and NPH patients. Also,
our findings of increased oxidation of TTR in CSF from
AD patients is in conflict with earlier reports using linear
MALDI-TOF MS for quantitation of TTR isoforms where
less TTR-oxidation was found [9]. The previous study,
however, analyzed directly on crude CSF dried down with
matrix on target and overall find much higher oxidation
of TTR, especially in control samples, than in the present
study. Also, the spectra are less well resolved and proteins
less confidently identified. Thus, method differences, the
contribution from other proteins and their isoforms (e.g.
cystatin C) in the specific m/z-range, and the contribution
from ex vivo oxidation caused by differences in sample
handling may all underlie the discrepancy between the
present work and the previous report.
In the present study we furthermore incidentally confirm
that the NPH group exhibits a unique biomarker profile
with significantly more reduced Aβ1-42 values than AD
but normal tau levels as previously documented [36-38].
Others have observed a similar reduction of Aβ1-42 in
NPH but with concurrent reduction of the levels of the
two tau species [39,40]. Our data indicate that a larger
prospective study of the diagnostic use of quantitation
of oxidative TTR isoforms in patients presenting with
symptoms of dementia together with standard biomarkers
is warranted and that more simple rapid methods, e.g.
based on immunochemical reagents specific for the non-
modified Cys-10 epitope should be developed.Competing interests
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